These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 19429640)

  • 1. Phase II trial of concurrent chemoradiotherapy with S-1 plus cisplatin in patients with unresectable locally advanced squamous cell carcinoma of the head and neck: Japan Clinical Oncology Group Study (JCOG0706).
    Nakamura K; Tahara M; Kiyota N; Hayashi R; Akimoto T; Fukuda H; Fujii M; Boku N
    Jpn J Clin Oncol; 2009 Jul; 39(7):460-3. PubMed ID: 19429640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Concurrent chemoradiotherapy (CRT) with S-1 and cisplatin (CDDP) in patients (pts) with locally advanced head and neck cancer (HNC)].
    Tahara M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():167-71. PubMed ID: 16897996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction chemotherapy with S-1 plus cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck.
    Choi YJ; Chung JS; Shin HJ; Cho GJ; Wang SG; Lee BJ; Cho BM; Joo YD; Sohn CH
    J Laryngol Otol; 2008 Aug; 122(8):848-53. PubMed ID: 18047761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck cancer.
    Ohashi T; Ohnishi M; Tanahashi S; Murai M
    Jpn J Clin Oncol; 2011 Mar; 41(3):348-52. PubMed ID: 21109512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
    Chang PM; Chen PM; Chu PY; Wang LW; Tai SK; Tsai TL; Huang JL; Wang YF; Chang SY; Yang MH
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):9-17. PubMed ID: 18343925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II study of s-1 plus cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer.
    Fujii M; Tomita K; Nishijima W; Tsukuda M; Hasegawa Y; Ishitoya J; Yamane H; Homma A; Tomita T
    Jpn J Clin Oncol; 2010 Mar; 40(3):214-21. PubMed ID: 19934112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
    Brizel DM; Murphy BA; Rosenthal DI; Pandya KJ; Glück S; Brizel HE; Meredith RF; Berger D; Chen MG; Mendenhall W
    J Clin Oncol; 2008 May; 26(15):2489-96. PubMed ID: 18487568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I/II trial of chemoradiotherapy concurrent with S-1 plus mitomycin C in patients with clinical Stage II/III squamous cell carcinoma of anal canal (JCOG0903: SMART-AC).
    Takashima A; Shimada Y; Hamaguchi T; Ito Y; Nakano A; Nakamura K; Shibata T; Fukuda H; Moriya Y;
    Jpn J Clin Oncol; 2011 May; 41(5):713-7. PubMed ID: 21467080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction chemotherapy followed by concurrent chemoradiotherapy in advanced head and neck squamous cell carcinoma.
    Barone C; Grillo R; Dongiovanni D; Birocco N; Rampino M; Redda MG; Garibaldi E; Munoz F; Pecorari G; Cavalot A; Garzinodemo P; Buffoni L; Ciuffreda L; Ricardi U; Cortesina G; Giordano C; Fasolis M; Berrone S; Bertetto O; Schena M
    Anticancer Res; 2008; 28(2B):1285-91. PubMed ID: 18505067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. concomitant chemoradiotherapy with mitomycin C and cisplatin in advanced unresectable carcinoma of the head and neck: phase I-II clinical study.
    Strojan P; Karner K; Smid L; Soba E; Fajdiga I; Jancar B; Anicin A; Budihna M; Zakotnik B
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):365-72. PubMed ID: 18394816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution.
    Adelstein DJ; Saxton JP; Rybicki LA; Esclamado RM; Wood BG; Strome M; Lavertu P; Lorenz RR; Carroll MA
    J Clin Oncol; 2006 Mar; 24(7):1064-71. PubMed ID: 16505425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of chemoradiotherapy with the combination of S-1 plus cisplatin for patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
    Tahara M; Minami H; Kawashima M; Kawada K; Mukai H; Sakuraba M; Matsuura K; Ogino T; Hayashi R; Ohtsu A
    Cancer Sci; 2011 Feb; 102(2):419-24. PubMed ID: 21134076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer.
    Shinoto M; Shioyama Y; Sasaki T; Nakamura K; Ohura H; Toh Y; Higaki Y; Yamaguchi T; Ohnishi K; Atsumi K; Hirata H; Honda H
    Am J Clin Oncol; 2011 Aug; 34(4):362-6. PubMed ID: 20686402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck: a phase II trial.
    Merlano M; Russi EG; Numico G; Colantonio I; Garrone O; Pelissero A; Granetto C; Gasco M; Di Costanzo G; Heouaine A; Vigna Taglianti R; Cipolat M
    Radiother Oncol; 2005 May; 75(2):193-6. PubMed ID: 16086909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combination therapy with S-1 and CDDP for head and neck cancer].
    Fujii M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():150-4. PubMed ID: 16897992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biweekly paclitaxel, cisplatin, tegafur, and leucovorin as neoadjuvant chemotherapy for unresectable squamous cell carcinoma of the head and neck.
    Wang HM; Liao CT; Chang TC; Chen JS; Liaw CC; Chen IH; Tsang NM
    Cancer; 2004 Oct; 101(8):1818-23. PubMed ID: 15386306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
    Kiyota N; Tahara M; Kadowaki S; Fuse N; Doi T; Minami H; Ohtsu A
    Jpn J Clin Oncol; 2009 Apr; 39(4):225-30. PubMed ID: 19211574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for severe Dysphagia after concurrent chemoradiotherapy for head and neck cancers.
    Koiwai K; Shikama N; Sasaki S; Shinoda A; Kadoya M
    Jpn J Clin Oncol; 2009 Jul; 39(7):413-7. PubMed ID: 19383615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical phase trial of concurrent chemoradiotherapy combined TS-1 and nedaplatin].
    Takemura H; Kobayashi S; Katsuno M; Asano R; Morimoto M; Tachibana S; Kubota H; Iida M; Kadokura Y; Sanbe T
    Gan To Kagaku Ryoho; 2005 Dec; 32(13):2065-9. PubMed ID: 16352930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas.
    Medina JA; Rueda A; de Pasos AS; Contreras J; Cobo M; Moreno P; Benavides M; Villanueva A; Alba E
    Radiother Oncol; 2006 Apr; 79(1):34-8. PubMed ID: 16626826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.